<DOC>
	<DOCNO>NCT00204620</DOCNO>
	<brief_summary>The aim trial evaluate efficacy bendamustin patient metastatic soft tissue sarcoma progress anthracycline-baesd chemotherapy ass treatment toxicity .</brief_summary>
	<brief_title>Bendamustin Hydrochloride Patients With Soft Tissue Sarcoma ( STS )</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologically confirm metastatic nonresectable soft tissue sarcoma Evidence progression relapse anthracyclinebased and/ ifosfamidebased chemotherapy At least 1 bidimensionally measurable tumor lesion accord RECIST criterion No previous radiation therapy measurable lesion Willingness receive regular followup Life expectancy 3 month ECOG status &gt; = 2 Patients age 18 year beyond leucocyte &gt; 2500/µl , thrombocytes &gt; 75000/µl ) Serum creatine &lt; 1,5 time upper limit normal value , GFR &gt; 60/ml Written patient inform consent Ability give inform consent Previous concurrent radiation index lesion ( radiation single lesion allow index lesion ) Insufficient liver function ( bilirubin &gt; 1.5 upper limit normal , prolongation PT aPTT &gt; 1.5 upper limit normal ; ASAT ALAT &gt; 3 upper limit normal ( patient liver metastasis ASAT ALAT &gt; 5 upper limit normal ) Active infection Prior therapy Bendamustin hydrochloride Prior malignancy ( adequately treat carcinoma situ ( CIS ) cervix , bladder urothelium , basal cell carcinoma adenoma colon include pTIS , pTIN ) , unless treat curative intent without evidence disease &gt; 5 year Symptomatic cardio and/or cerebrovascular disease ( NYHAScale III° ) Interval since last chemotherapy &lt; 4 week Evidence CNSmetastases Evidence pregnancy lactation Woman childbearing potential without reliable method birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>